乳癌名醫：饒坤銘　　　　　　　　　　

現職： 長庚紀念醫院高雄分院 血液腫瘤科主治醫師

學歷 :

1. Medical college of Chung Shang Medical University,Taiwan,R.O.C.

2. Worked as a Visiting Scientist in the Department of Molecular and Cellular Oncology at The University of Texas M.D. Anderson Cancer Center

3. An undergraduate of Graduate Institute of Clinical Medical Sciences , Chang Gung University

經歷：

1. From August 1,1994 to July 31,1997,as a first to third year resident in Department of Internal Medicine of  Chang Gung Memorial Hospital,     Taipei,Taiwan,R.O.C.

2. From  August 1,1997 to July 31,1999 as a first to second year fellow in Division of  Hemato-Oncology,Chang Gung Memorial Hospital, Taipei, Taiwan, .

PUBLISH :

1. Rau, Kun Ming; Liao, Zong-Chi; Zhuang, Zheng-Keng; Li Jin-Hui,: Successful surgical treatment of  solitary adrenal metastases from Non-small cell lung cancer : case report. Chang Gung Medical Journal. Vol. 22, p.282-286, June. 1999.

2. Rau, Kun Ming; Kong, Hong-You; Cha, T-L; Miller, S-A; Hung, Ming-Chi: The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocrine-Related Cancer, vol 12, p.511 - 532 2005.

3. Rau, Kun Ming; C-P Day; L Qiu; Liu C-W; H-P Kuo; X Xie; G Lopez-Be;    Gn Hortoba; Hung, Ming-Chi: Mutant bik expression mediated by the enhanced minimal topoisomerase IIA promoter selectively suppressed breast tumors in an animal model. Cancer Gene Therapy. p.1-14,  Sep.2006

4. Yan, Dun-Hua; Rau, Kun-Ming; Hung, Ming-Chi: Antimetastasis. Cancer Gene Therapy, vol 19, p.287-298, 2004.

5. Chen, Ren-Shi; Huang, Ren-Sheng; Yang, Zai-Sheng; Lin,Yong-Chang; Wang, Hong-Ming; Liao, Ji-Ding; Rau, Kun-Ming : Phase I dose escalation study of Oxaliplatin combined with drugs tegafur-uracil and leucovorin in patients with advanced gastric cancer. Anti-Cancer Drugs, vol 16 p.16-47, 2005

6. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Therapy, vol 11, p.740-7, 2004.

7. Lee, Shau-Suan; Chen, Wei-Shi; Tang,Yeh; Rau, Kun-Ming, Chen, Yeng-Yang; Huang,Tai-Lin; Liu, Jia-Shou; Huang, Chen-Hua : Incidence of ischemic stroke post-chemotherapy : A petrospective review of 10,963 patients. Clinical Neurology and Neurosurgery, vol 108, p.150-156, 2006.

8. Tai-Lin Huang; Yeh Tang; Kun-Ming Rau; Yeng-Yang Chen; Cheng Hua Huang :  Extrapulmonary small cell carcinoma – A medical center’s experience. Chang Gun Medical Journal, vol 29, p.590-595, 2006.

9. Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas : No significant correlations with clinicopathological variables and treat. International journal of pediatric otorhinolaryngology, Vol.71, p.447-455, 2007

10. Lee, Shau-Suan, Kun-Ming Rau, Yi-Chun Chiu.:Upper gastrointestinal bleeding as the initial manifestation of lung adenocarcinoma metastatic to the stomach. Respiratory MD\edicine extra, Vol.3, p.67-70, 2007.

POSTER：
1. Selective Breast Tumor Growth Suppression Mediated by the Enhanced Breast Cancer-Specific Promoter
--發表於American Society of Gene Therapy’s 7th Annual Meeting

2. 經肝動脈化學治療對晚期肝癌病患之療效
The Therapeutic Effect of Intra-hepatic Arterial Chemotherapy to Advanced Hepatoma. Kun-Ming Rau, M.D.   Yeng-Young Chen, M.D. King-Wah Chiu, M.D.  Yu-Fan Cheng, M.D.       

REASERCH：
1.¨ Phase I, II study of oxaliplatin combined with oral tegafur-uracil and   leucovorin in patients with advanced gastric cancer.

2.¨ Phase II study of pegylated liposomal doxorubicin combined with cyclophosphamide/5-FU as second line chemotherapy in the treatment of  metastatic breast cancer —XMRP 840091

3.¨ Phase II Study of UFUR in Combination with Gemcitabine and Cisplatin in Patients with Advanced Bladder Cancer

4.¨ Phase III study of EPO-alfa as an adjuvant therapy in   metastatic breast cancer patients accepting the first line chemotherapy—XMRP 850171

5.¨ VEGF as a predictive marker to the therapeutic effect of hepatoma intraarterial chemotherapy.—CMRPG 840681